Mesoblast rallies after reporting 60% revenue jump on Ryoncil sales

The news: Biotech company Mesoblast reported a 60% increase in quarterly revenue to USD35.1 million ($52.4 million), driven by sales of its cell therapy Ryoncil for the quarter ended 31 December 2025.

The numbers: Shares had lifted 8.06% to $2.95 at 10:19am AEDT.

The context: Ryoncil is the first mesenchymal stromal cell therapy designed to treat children with steroid-refractory acute graft-versus-host disease, a high-mortality complication of stem cell transplants, and is the first FDA-approved therapy of its kind.

The revenue growth helped strengthen Mesoblast’s balance sheet following the company’s announcement that it had secured a new USD125 million ($186 million) facility to lower its cost of capital and provide flexibility for strategic partnerships and commercialisation.

What they said: "Our strong balance sheet, continued growth in quarterly sales of Ryoncil, and the lower-cost financing facility provides greater flexibility for strategic partnerships and pursuit of label expansions for Ryoncil," Mesoblast CEO Dr Silviu Itescu said.